Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised Phase 3 Study of Rituximab in High-Risk Patients With Diffuse Large B-Cell Lymphoma Who Received a First-Line Consolidative Chemotherapy With Autologous Stem Cell Transplant (ASCT).

NCT00169169 is registered in ClinicalTrials.gov with Lymphoma Study Association as lead sponsor.

NCT NCT00169169
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00169169 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised Phase 3 Study of Rituximab in High-Risk Patients With Diffuse Large B-Cell Lymphoma Who Received a First-Line Consolidative Chemotherapy With Autologous Stem Cell Transplant (ASCT).
Lead sponsor
Lymphoma Study Association
Phase
Phase 3
Overall status
Terminated
Start date
October 31, 1999
Completion date
August 31, 2005
Enrollment
430
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cd20-positive large b-cell lymphoma